Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Allergovit is a brand of allergen immunotherapy (also known as desensitisation or specific immunotherapy) used primarily for the treatment of severe hayfever and allergic rhinitis caused by grass or tree pollens. It consists of natural pollen extracts (allergoids), which are modified allergens designed to reduce allergenicity while retaining their ability to induce immune tolerance. The therapy works by gradually exposing patients to increasing doses of the relevant pollen allergens via subcutaneous injection, aiming to "reset" or modulate the immune response and reduce allergic symptoms over time. The mechanism involves immunomodulation—shifting the immune system away from an IgE-mediated allergic response towards tolerance. Clinical studies show significant long-term symptom reduction in most patients after a course lasting approximately 30 months[1][2][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Allergovit.